Johnson & Johnson also increased its full-year sales and profit forecast.
Johnson & Johnson beats Q2 2026 Wall Street estimates and raises full-year guidance as sales top $25B, driven by oncology and MedTech.
The healthcare giant beat second-quarter forecasts and raised its outlook.